✨ Free AI Report
Forte Biosciences, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Forte Biosciences, Inc.
Company Research

Forte Biosciences, Inc.: Business Overview, Financials & Competitive Analysis

Forte Biosciences, Inc. scores 6/10 on the AskCyborg Cyborg Score (Solid). Clinical-stage immunology biotech with positive Phase 1b data and FDA Fast Track in celiac disease, offset by high cash burn and extended timeline to profitability. Forte Biosciences has surged over 130% since November 2025 in anticipation of 2026 data for FB102 in celiac, vitiligo, and alopecia areata. However, FBRX.

What is Forte Biosciences, Inc.'s industry? Forte Biosciences, Inc. (fortebiorx.com) operates in Immunology Drugs. AskCyborg classifies Forte Biosciences, Inc. under Immunology Drugs in its company registry.

Forte Biosciences is a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases. The company's lead candidate, FB-102, is a proprietary anti-CD122 monoclonal antibody therapeutic ...

6/ 10Solid

Cyborg Score thesis

Clinical-stage immunology biotech with positive Phase 1b data and FDA Fast Track in celiac disease, offset by high cash burn and...

Read the full analyst-debate transcript →
Industry Immunology Drugs
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 5, 2026
AI-Verified Research
30+ Page Report

Get the Latest Forte Biosciences, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Forte Biosciences, Inc.

AskCyborg analysts argue the bull and bear cases for Forte Biosciences, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Forte Biosciences, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Forte Biosciences, Inc. Overview

Pro stress-test →

Forte Biosciences is a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases. The company's lead candidate, FB-102, is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications.

Strategic Profile

Pro stress-test →

FB102 received Fast Track Designation from the FDA in celiac disease, highlighting the unmet need. Based on the strength of the positive results from the FB102 phase 1b CeD trial, which was reported in June 2025, the company looks forward to the phase 2 data further validating FB102 for the treatment of celiac disease. The company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.

Competitive Landscape

Pro stress-test →

FB102 faces a crowded competitive landscape with 14+ rival programs in development for celiac disease. The company competes in the autoimmune therapeutic space against both established biologics manufacturers and other clinical-stage immunology companies targeting similar pathways and indications.

Industry Context

Forte Biosciences, Inc. operates in Immunology Drugs.

Key facts

Founded: Not specified in available sources · Headquarters: Dallas, Texas, US · Employees: Not disclosed · Revenue: N/A (pre-revenue, clinical stage) · Market cap: $325M (as of June 5, 2026)

What the analysts stress-tested

The top findings that survived the multi-agent debate for Forte Biosciences, Inc..

  • The company held $58.2 million in cash at March 31, 2026 and subsequently raised $172.5 million in gross proceeds in an April 2026 equity offering
  • Net loss of $22.1 million in Q1 2026 (up from $15.7 million a year earlier), driven mainly by higher R&D spending which rose to $20.5 million, largely from FB102 Phase 2 celiac disease and Phase 1b vitiligo and alopecia areata trials
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • April 2026Raised $172.5 million in gross proceeds through equity offering at $26.27 per share
  • May 2026Announced Q1 2026 results with $22.1 million net loss and achieved FDA Fast Track Designation for FB102 in celiac disease
  • +1 moreTrack every material event for Forte Biosciences, Inc. as it happens. Explore monitoring →
Get alerted when Forte Biosciences, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Immunology therapeutics (autoimmune targets)Established immunology and autoimmune disease therapies→Autoimmune and inflammatory therapeuticsLarge-cap biotech with extensive autoimmune portfolio→Clinical-stage immunology programsClinical-stage competitor in autoimmune space→

Compare Forte Biosciences, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Forte Biosciences, Inc. operates in Immunology Drugs. See how the rest of the sector scores on the Cyborg framework.

Browse Immunology Drugs research →
NEW · MCP server

Ask your AI assistant about Forte Biosciences, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Forte Biosciences, Inc. and its top competitor on Cyborg Score”
“What did Forte Biosciences, Inc. do this quarter?”
“Is Forte Biosciences, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Forte Biosciences, Inc. do?+
Forte Biosciences is a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases. The company's lead candidate, FB-102, is a proprietary anti-CD122 monoclonal antibody therapeutic ...
What is Forte Biosciences, Inc.'s Cyborg Score?+
Forte Biosciences, Inc. has a Cyborg Score of 6/10 (Solid). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Forte Biosciences, Inc.'s main competitors?+
Named competitors include Immunology therapeutics (autoimmune targets), Autoimmune and inflammatory therapeutics, Clinical-stage immunology programs. The full competitive landscape is in the AskCyborg report.
How can I get the full Forte Biosciences, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Forte Biosciences, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Forte Biosciences, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.